No photo of Rasmus Bisbjerg

Rasmus Bisbjerg


    Research activity per year

    Personal profile


    Prostate cancer

    Main research areas

    Mainly company-sponsored research

    Current research


    FASE II: A phase 2, open-label, single-arm, efficacy, and safety study of an investigational (Enzalutamide) drug in patients with hormone-naïve prostate cancer - now open-label

    Role: Principal Investigator


    PRIMORDIUM (2021-): A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Follow-up of PSMA-PET-Negative Patients

    Role: Principal Investigator


    DAROL (2022-): Darolutamide Observational Study in nonmetastatic castration-resistant prostate cancer patients

    Role: Principal Investigator




    BraVac: A Phase 2, Double-Blind, Placebo-Controlled Study of RV001V in Men with Biochemical Failure following Curatively Intended Therapy for Localized Prostate Cancer

    Role: Sub-Investigator


    PROSPER: A multinational, phase 3, randomized, double-blind, placebo-controlled efficacy and safety study of an investigational drug in patients with non-metastatic castration-resistant prostate cancer.

    Role: Sub- Investigator and Principal Investigator


    ARCHES: A multinational, phase 3, randomized, double-blinded, placebo-controlled efficacy and safety study of an investigational drug plus Androgen Deprivation Therapy versus placebo + Androgen Deprivation Therapy in patients with metastatic hormone-sensitive prostate cancer

    Role: Sub-Investigator


    TERRAIN: A randomized, double-blind, phase 2, efficacy and safety study of an investigational drug versus Bicalutamide in castrate men with metastatic prostate cancer – open-label after.

    Role: Sub-Investigator


    CORAL: A randomized, multi-site, double-blinded, double-dummy, active control, parallel-group, multidose, efficacy, safety, and tolerability phase 3 study of an oral investigational drug versus Morphine in subjects with chronic moderate to severe pain related to cancer

    Role: Sub-Investigator


    OREXO: A phase 2, randomized, double-blind, placebo-controlled, dose-finding trial using a sublingual investigational drug to alleviate pain associated with a prostate biopsy procedure

    Role: Sub-Investigator


    GALAHAD: A phase 2 efficacy and safety study of an investigational drug in men with metastatic castration-resistant prostate cancer with DNA-repair anomalies.

    Role: Principal Investigator


    PREVAIL: A multinational, double-blind, randomized, placebo-controlled phase 3 trial of an investigational drug + GnRH therapy in chemotherapy-naïve patients with progressive metastatic CRPC who have failed ADT - now open-label

    Role: Sub-Investigator


    PROSPECT/PROSTVAC: A randomized, double-blind, phase 3 efficacy trial of an investigational vaccine in men with asymptomatic or minimally symptomatic metastatic castrate-resistant prostate cancer

    Role: Sub-Investigator


    FERRING:  A prospective observational safety study in patients with advanced prostate cancer treated with a GnRH antagonist or a GnRH agonist

    Role: Sub-Investigator


    HERO: A multinational phase 3, randomized, open-label, parallel Group study to evaluate the safety and efficacy of an investigational drug in men with advanced prostate cancer

    Role: Principal Investigator


    PREMISE: A European prospective observational study assessing the efficacy and outcomes associated with AR-targeted treatment in patients with metastatic castration-resistant prostate cancer.

    Role: Sub-Investigator

    Potential conflicts of interest

    Advisory board member for the “Danish Medicines Council” regarding Prostate cancer (2020 - )


    Dive into the research topics where Rasmus Bisbjerg is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
    • 1 Similar Profiles

    Collaborations and top research areas from the last five years

    Recent external collaboration on country/territory level. Dive into details by clicking on the dots or